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Abstract
Type 4 phosphodiesterase (PDE4) inhibitors are emerging new treatment for a number of disorders
including asthma and chronic obstructive pulmonary disease. Here we report the biochemical
characterization on the second generation inhibitor (+)-1 (L-869298, IC50 = 0.4 nM) and its
enantiomer (−)-1 (L-869299, IC50 = 43 nM), and their co-crystal structures with PDE4D at 2.0 Å
resolution. In spite of the 107-fold affinity difference, both enantiomers interact with the same sets
of residues in the rigid active site. The weaker (−)-1 adopts an unfavorable conformation in order to
preserve the pivotal interactions between the Mg-bound waters and N-oxide of pyridine. These
structures support a model in which inhibitors are anchored by the invariant glutamine at one end
and the metal-pocket residues at another end. This model provides explanation for most of the
observed structure-activity relationship and the metal ion dependency of the catechol-ether based
inhibitors and should facilitate their further design.
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Introduction
Cyclic nucleotide phosphodiesterases (PDEs) are binuclear metallohydrolases that catalyze the
hydrolysis of second messengers cAMP and cGMP. Eleven families of PDEs, encoded by
twenty one genes and sharing a conserved catalytic domain of about 300 amino acids, are
differentially expressed in various human tissues.1–5 Over the last two decades, a number of
PDE inhibitors have been developed for therapeutic usage. For examples, cilostazol, a PDE3
inhibitor, is beneficial in the treatment of macrovascular disorders such as intermittent
claudicating.6 Ibudilast, an effective treatment for asthma, cerebrovascular disorders, and
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allergic conjunctivitis, is a PDE4-preferred inhibitor.7 The PDE5 inhibitors, sildenafil,
vardenafil, and tadalafil, are widely used in the treatment of male erectile dysfunction.8
The cAMP-specific type 4 phosphodiesterases are encoded by 4 genes (PDE4A to PDE4D)
and are particularly abundant in inflammatory cells, immune cells, sensory neurons, airway
smooth muscles, and airway epithelium. Inhibition of PDE4 will elevate cAMP and initiate a
series of biological responses, including blockage of cell trafficking and proliferation,
attenuation of the production of inflammatory cytokines and reactive oxygen species, and
enhancement of the mucociliary clearance through CFTR activation.9 PDE4 inhibitors are
clinically efficacious in treatment of asthma and chronic obstructive pulmonary disease
(COPD) and in models of rheumatoid arthritis, multiple sclerosis, septic shock and neurological
disorders.10–18 They may emerge as new therapeutics for a number of disorders in the near
future.13
The promise of identifying additional novel therapeutics among family-specific PDE inhibitors
has led to an intense effort to study their interaction at the atomic level. The understanding of
ligand binding and PDE functions has been greatly enriched by the crystal structures of the
catalytic domains of PDE1B,19 PDE2A,20 PDE3B,21 PDE4B and PDE4D,19, 22–29 PDE5A,
19,26,30 PDE7A,31 and PDE9A.32 In addition to solidifying the bimetallic catalytic
machinery hypothesis of PDEs,9 these structures have identified a number of interactions such
as the glutamine-mediated hydrogen bond for nucleotide differentiation and shed light on the
common and selective recognition of various inhibitors.19,25,28 However, it remains unclear
how PDE recognizes enantiomeric inhibitors that often show over ten fold affinity difference.
Here we report the kinetic and structural studies on two PDE4 enantiomeric inhibitors, (+)-1
and (−)-1, Fig. 1), and their complexes with PDE4D. Comparison of the cocrystal structures
reveals that this pair of enantiomers interacts with the similar PDE4 residues, but the weaker
inhibitor (−)-1 adopts a restrained conformation in order to preserve the other key interactions
and to fit into the rigid pocket.
Results and Discussion
Biochemical characteristics of the enantiomeric PDE4 inhibitors
The more potent enantiomer (+)-1, with its absolute configuration assigned previously by x-
ray crystallographic analysis (Fig. 1), is a non-emetic 2nd generation PDE4-specific inhibitor
exhibiting good in vivo efficacy in several animal models of pulmonary function with a wide
therapeutic index on emesis and prolongation of the QTc interval.33 It potently inhibited all
four PDE4 subtypes with the IC50 values of 0.4, 0.4, 1.1 and 0.3 nM against the catalytic
domains of PDE4A, PDE4B, PDE4C and PDE4D, respectively. The less potent isomer
(−)-1, with an enantiomeric purity at 99.7%, has the corresponding IC50 values of 56, 40, 135,
and 43 nM, respectively (Table 1). The potencies of (+)-1 and (−)-1 against four representative
full-length PDE4 variants of PDE4A4, PDE4B2, PDE4C2 and PDE4D3 are similar to those
of the catalytic domains (data not shown). A linear dependence of the IC50 values for (+)-1
inhibition of PDE4A on cAMP concentration was obtained, indicating that it is an active site-
directed competitive inhibitor (Fig. 2a). The linear plot yielded an apparent Ki value of 0.43 ±
0.07 nM. In addition, the activity of (+)-1-inhibited PDE4A was completely recovered within
90s after a 120-fold dilution, indicating that it is a rapidly reversible inhibitor (Fig. 2b). These
data support that they are active site-directed and rapidly reversible inhibitors with comparable
potency against the four PDE4 isoforms.
Conformational conservation of the PDE4D catalytic domain
The cocrystals of PDE4D2 catalytic domain (amino acids 79–438) in complex with (+)-1 and
(−)-1 contain four PDE4D2-inhibitor complexes in the asymmetric unit, which are apparently
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associated into a tetramer in the crystal state. The monomeric PDE4D2 molecule consists of
16 helices and two divalent metal ions (Fig. 3), as previously reported.25 A superposition
between the monomers of the tetramers yields root-mean-squared (RMS) deviations of 0.38
and 0.32 Å for the backbone atoms of residues 79–412 in the PDE4D2-(+)-1 and PDE4D2-
(−)-1 crystals, suggesting a conformational similarity within the tetramer. The superposition
of the monomers of the PDE4D2-(−)-1 tetramer over the corresponding ones of the unliganded
PDE4D2 or the PDE4D2-(+)-1 complex yields the RMS deviations of 0.21 and 0.28 Å for
backbone atoms in the catalytic domains, respectively. These comparisons suggest no
significant changes of the overall conformation of the catalytic domains upon enantiomer
binding, and the rigidity of the PDE4D2 active site.
Binding of the enantiomeric inhibitors
In spite of the 107-fold affinity difference, (+)-1 and (−)-1 bind to the active site of PDE4D2
with similar orientations and interact with the same residues (Fig. 3, Table 2). The structures
of the two enantiomers are divided into five subgroups and labeled as CORE and R1 to R4 in
Fig. 1 to facilitate discussion. Since most subgroups of the two inhibitors interact with similar
residues of PDE4D2, the discussion below will not differentiate them unless different contacts
are observed. The catechol-ether group (CORE in Fig. 1) of both enantiomers forms two
hydrogen bonds with the side chain of Gln369, an invariant residue among all PDEs (Table 2).
In addition, its phenyl ring stacks against Phe372 and also contacts with Tyr159, Asn321,
Ile336, and Gln369 via van der Waals’ forces. The difluoromethyl group (R1) is located in a
small pocket interacting with Asn321, Pro322, Tyr329, Trp332, Thr333, Ile336, and Gln369.
The cyclopropyl group (R2) sits in a hydrophobic pocket, interacting with residues Met357,
Gln369 and Phe372. The hexafluoro-propyloxy group and the thiazole ring (R3) are surrounded
by Met273, Phe340, Met357, Phe372, and Ile376.
The pyridine-N-oxide (R4) orients towards the metal binding pocket and interact with residues
Thr271, Met273, Asp318, and Leu319 (Figs. 3 & 4). The oxygen of the N-oxide in (+)-1 (O4
in Fig. 1 and Table 2) forms two hydrogen bonds with water molecules W7 and W8 that are
bound respectively to His204 and Met273. However, only one hydrogen bond between W7
and the oxygen O4 of pyridine-N-oxide is found in the PDE4D2-(−)-1 complex. The hydrogen
bond (2.9 Å) between pyridine-N-oxide and W8 in (+)-1 became a polar interaction with an
average distance of 3.4 Å in the PDE4D2-(−)-1 structure (Fig. 4). The R4 group interacts
indirectly with the divalent metals via a network of bound water molecules. There are three
waters (W1, W2 and W3) that form van der Waals’ interactions with the pyridine ring. A Mg-
bound W3 is 3.5 Å to the nitrogen of N-oxide in (+)-1 and 3.1 Å in (−)-1. Water W3 also
impacts the inhibitor binding via a hydrogen bond relay through W7 (Fig. 4). These indirect
interactions imply a role of the metal ions in the inhibitor binding.
On the basis of the 107-fold affinity difference, one might suspect that (+)-1 and (−)-1 would
interact with somewhat different residues. However, the cocrystal structures revealed that all
subgroups of the inhibitors are bound similarly (Figs. 3 & 4, Table 2). The conformational
difference of the bound enantiomers is limited to the arrangement of the four single bonds
around the chiral center, which is in a proximate mirror-image relationship (Fig. 4d). Among
the possible reasons, the change of the hydrogen bond between pyridine-N-oxide and water
W8 in (+)-1 to a polar interaction in (−)-1 (Fig. 4) may account for a portion of the affinity
difference. Another difference lies at the conformation of the bound enantiomers. While most
subgroups of (+)-1 and (−)-1 are superimposable to each other, the dihedral angle around the
C5-C9 bond (Fig. 1) is very different. This dihedral angle is about −70° relative to R4 in
(+)-1, which is closer to the energetically favored “staggered” conformation of −60°. In
comparison, the dihedral angle in (−)-1 is about 20°, which is closer to the unfavorable
“eclipsed” conformation of 0°. It appears that, in order to preserve the favorable pyridine-N-
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oxide interaction at the metal pocket and, in the meantime, to accommodate the chirality,
(−)-1 is forced into a distorted conformation in the rigid PDE4D active site.
Metal pocket serves as an anchor for high affinity binding of inhibitors
Previous structural studies have established that the common catalytic machinery of PDEs
comprises two divalent cations with different affinities. The anomalous scattering of the PDE
crystal at the absorption edge of zinc supports that the tightly bound cation is a Zn2+ ion.22
Even though a number of divalent cations including Mg2+, Co2+, Zn2+ and Ni2+ can support
PDE catalysis in vitro, the loosely bound metal ion is likely a Mg2+ ion in vivo, since only its
EC50 value at activating catalysis is within its free intracellular concentration range.34 The
structures of PDEs in complex with various inhibitors have revealed two common factors for
binding of most PDE inhibitors: the hydrophobic clamp for the catechol-ether ring of rolipram
and the hydrogen bonds between catechol-ether oxygen and Gln369.25,27–29,32 The
structures of PDE4D in complex with (+)-1 and (−)-1 support the early observation, but also
suggest that hydrogen-bond network near the metal center serves as the third element for high
affinity binding of PDE inhibitors. The hydrogen bonds with Gln369 and the hydrophobic
clamp interaction alone appear to be insufficient for securing a high affinity inhibitor
interaction. Earlier binding studies have uncovered that the Mg ion is responsible for eliciting
the cAMP binding and the high affinity interaction of many catechol-ether based PDE4
inhibitors (Fig. 1).9,35 For example, the productive and high affinity cAMP binding decreased
from 2 μM to a nonproductive binding of 179 μM, and the binding of cilomilast decreased
from a Kd of 42 nM to > 4000 nM upon the removal of the Mg. The molecular origin of this
Mg-dependency for cilomilast (Fig. 1) has now been resolved by the presence of two hydrogen-
bonds between the oxygens of its carboxylate and Mg-bound waters in its cocrystals.28 Upon
the removal of Mg, interaction of PDE4A with (+)-1 decreased by approximately 275-fold to
a Kd of ~ 110 nM in comparison to its original Ki of 0.4 nM (data not shown). The interactions
of the Mg-bound water (W3) directly and indirectly (through W7) with the N-oxide likely
contribute significantly to this affinity difference. In short, this study supports a coordinated
“two point anchoring model”, in which the hydrogen bonding to the glutamine at one end and
the hydrophilic interactions in the metal pocket at the other end act as the pivotal factors in
eliciting the high affinity binding of catechol-ether based PDE4 inhibitors.
Implication on PDE4 inhibitor optimization
Numerous PDE4 inhibitors with diverse structures have been synthesized over the past years,
as exemplified in the earlier comprehensive review.11 The structures of PDE4B and PDE4D
in complex with a number of more advanced inhibitors sharing the catechol-ether scaffold,
including rolipram, cilamilast, roflumilast, mesopram, and piclamilast (Fig. 1), have been
reported.23,25,28 Superposition of these structures revealed several common interacting
features. The catechol-ether group (CORE in Fig. 1) appears to serve as a common element in
the formation of the hydrogen bonds with the invariant glutamine, which likely contributes
partially to the binding affinity.19,23–29,32 Other components for inhibitor binding in this
area are the stacking against a conserved phenylalanine and the hydrophobic interactions with
Ile336 and Phe340 in PDE4D2.25,28 It is interesting to note that the distance between (+)-1
(or (−)-1) and Phe340 is slightly longer than 4 Å, thus implying a general hydrophobic
environment for the interactions.
The residues interacting with the R1 group vary significantly across different PDE families
and may be, in principle, useful for improving family-specificity of inhibitors. However, this
sub-pocket is relatively small and accommodates only three or so atoms such as difluoromethyl
group. The R2 group sits in a hydrophobic pocket, and thus hydrophobic replacement of R2
group, such as replacing the cyclic propyl with the cyclic butyl, would not impact significantly
the binding affinity. On the other hand, the introduction of polar atoms into the pocket is
Huai et al. Page 4













unfavorable, as reflected by ~ 70-fold decreased affinity when R2 is CF3.33 The different
amino acids and volume of this sub-pocket among PDE4, 5, 7 and 927,31,33 offer the
opportunity to improve family-specificity of inhibitors through R2 modifications. The R3
subgroup orients to an open space which is surrounded by the hydrophobic residues Met273,
Phe340, Met357, Phe372 and Ile376. A hydrophobic group, such as the phenyl in CDP-840 (5
nM, PDE4D, Fig. 1), bis-trifluoromethyl-phenyl in L-826141 (0.3 nM) and bis-
trifluoromethyl-thiazole in (+)-1 (0.4 nM), significantly enhances the affinities of these
inhibitors, likely through desolvation contribution.36 The R4 group sits next to the central
catalytic machinery, the bimetallic ion center. This sub-pocket is formed by a set of highly
conserved residues across PDE families. The partial and/or rapidly reversible occupancy of
the weaker Mg site leads to the differential binding of inhibitors, including the high and low
affinity binding of rolipram.9 Therefore, the modification of R4, which is pivotal in eliciting





trifluoromethyl-2,2,2-trifluoro)ethyl)thiazolyl]ethyl}pyridine N-Oxide ((+)-1) and (R)-(−)-3-
{2-[(3-Cyclopropyloxy-4-difluromethoxy)phenyl]-2-[5-(2-(1-hydroxy-1-
trifluoromethyl-2,2,2-trifluoro)ethyl)thiazolyl]ethyl}pyridine N-Oxide ((−)-1) were prepared
as described previously.33 The enantiomeric purity of (+)-1 was approximately at 99%. Higher
enantiomeric purity was required for (−)-1 in forming the PDE4D cocrystal. The starting
(−)-1 with a 98.0% was further purified by HPLC using a CHIRALPAK AD column (eluting
with 10% ethanol in hexanes) and by crystallization from ethanol/pentane to give a white solid.
Analytical HPLC using the same conditions indicated that the enantiomeric purity of the final
(−)-1 was at 99.7%.
PDE4A, PDE4B, PDE4C and PDE4D activity assays
The hydrolysis of cAMP by the four PDE4 isoforms were monitored as previously described.
35 The enzymes used are the recombinant Gln-Thr (QT) versions of PDE4A, 4B, 4C and 4D,
which encode the catalytic domains of PDE4s and have been shown to be in a fully activated
conformation.9 They were generated by creating glutathione fusion constructs in frame with
the QT located within UCR2 of PDE4A4, PDE4B2, PDE4C2 and PDE4D3 sequences. These
QT constructs, encoding approximately the maximal common regions of all PDE4 variants,
were expressed and purified to homogeneity from Sf9 cells. Their PDE activity was monitored
using 0.1 μM [3H]-cAMP in a buffer containing 10 mM MgCl2, 1 mM EDTA, 100 mM KCl
and 20 mM HEPES (pH 7.5). Compounds were introduced via 2 μL of DMSO as vehicle which
exerted minimal perturbation on PDE activity. The IC50 values were similar to their apparent
Ki values under the conditions from the use of 0.1 μM cAMP in comparison with their similar
Km of ~ 2 μM.
Crystallization and data collection
The protein expression and purification of the catalytic domain of PDE4D2 (amino acids 79–
438) have been described previously.25 The protein-inhibitor complexes were prepared by
mixing 2 mM (+)-1 (or (−)-1) with 10 mg/mL PDE4D2 in a storage buffer of 50 mM NaCl,
20 mM Tris.HCl (pH 7.5), 1 mM β-mercaptoethanol, and 1 mM EDTA. The crystals of the
catalytic domain of PDE4D2 in complex with (+)-1 were grown by vapor diffusion against a
well buffer of 0.1 M HEPES (pH 7.5), 15% PEG3350, 25% ethylene glycol, 5% isopropanol,
and 5% glycerol at 4°C. The catalytic domain of PDE4D2 in complex with (−)-1 was
crystallized against a well buffer of 0.05 M HEPES (pH 7.5), 15% PEG3350, 25 % ethylene
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glycol, and 5% methanol at 4°C. Both crystals have the space group P212121. The diffraction
data were collected on beamlines X26C ((+)-1) and X25 ((−)-1) at Brookhaven National
Laboratory (Table 3), and processed with program HKL2000.37
Structure determination
The crystals of PDE4D2 in complex with inhibitors (+)-1 and (−)-1 contain a tetramer in the
crystallographic asymmetric unit. The structures were solved by molecular replacement
program AMoRe,38 using the catalytic domain of unliganded PDE4D2 as the initial model.
25 The tetramer of PDE4D2-(+)-1 and PDE4D2-(−)-1 were optimized by rigid-body
refinement of CNS.39 The electron density maps were improved by the density modification
package of CCP4.40 The atomic model was rebuilt by program O41 and refined by CNS (Table
3).
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Chemical structures of PDE4 selective inhibitors. (+)-1 or (−)-1 has the chiral center at
carbon-9, and can be divided into five subgroups (CORE and R1 to R4) to facilitate discussion.
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Kinetic properties of (+)-1. (A) Inhibition of PDE4A by (+)-1 with respect to increased cAMP
concentration. The linear response has an intercept of 0.43 ± 0.07 nM (apparent Ki) and a slope
of 0.19 ± 0.02 nM/μM cAMP. (B). Rapidly reversible PDE4A inhibition by (+)-1. The activity
(mean ± se, n = 3) of PDE4A inhibited with 15 nM (+)-1 was determined at 30, 60, 120, and
180 seconds following a 120-fold volume dilution. 100% activity represents the average of the
corresponding controls (with DMSO as vehicle). Recovery time represents the dilution time
plus the assay duration (60s) except for the 0s point for (+)-1, which represents the enzyme
activity in the presence of 15 nM (+)-1.
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PDE4D2-inhibitor structures. (A) Ribbon diagram of monomeric PDE4D2 catalytic domain.
(+)-1 and (+)-1 are shown as the green and golden sticks, respectively. Divalent metal Zn is
drawn as a red ball and Mg as a purple ball. (B) Binding of (+)-1 (green sticks and balls) and
(+)-1 (golden sticks) at the active site of PDE4D2. The residues of PDE4D2, which are involved
in binding with the inhibitors, are labeled. The four metal binding residues are shown in light
blue.
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Binding of (+)-1 and (−)-1 (L869298 and L869299) to the active site of PDE4D2. Stereoview
of electron density for (+)-1 (A) and (−)-1 (B). The omitted (2Fo-Fc) maps were contoured at
1.5σ and 1.0σ for (+)-1 and (−)-1, respectively. (C) Superposition of (+)-1 (green) over (−)-1
(golden). The oxygen of pyridine-N-oxide of (+)-1 forms two hydrogen bonds with waters W7
and W8 that bound to His204 and Met273 (dotted lines), respectively. However, (−)-1 forms
only one hydrogen bond with water W7 and has a distance of 3.4 Å to water W8. (D) Another
view of the superposition of (+)-1 over (−)-1. The three bonds around the chiral center are
related by a mirror symmetry and shown in purple color for (+)-1 and red for (−)-1. The R3
groups in (+)-1 and (−)-1 are omitted for a clear view of the enantiomeric configuration.
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Table 2
Interactions of (+)-1 and (−)-1 with PDE4D2
Hydrogen bonds
Inhibitor atom Protein atom Average distance (Å)
(+)-1 (−)-1
O1 … Gln369 NE2 3.13 ± 0.05 3.10 ± 0.04
O2 … Gln369 NE2 3.02 ± 0.08 2.99 ± 0.06
O4 … H2O (W7) 2.95 ± 0.11 2.56 ± 0.06
O4 … H2O (W8) 2.93 ± 0.12 3.43 ± 0.08
Van der Waals’ interactions of (+)-1 and (+)-1
difluoromethy1 Asn321, Pro322, Tyr329, Trp332, Thr333, Ile336, Gln369
Propyl ring Met357, Gln369, Phe372
phenyloxy Tyr159, Asn321, Ile336, Gln369, Phe372
pentyl ring Met273, Phe340, Phe372
F2 group Met273, Met357, Ile376
Pyridine-N-oxide Thr271, Met273, Asp318, Leu319













Huai et al. Page 15
Table 3
Statistics on diffraction data and structure refinement of PDE4D-inhibitors
Data collection (+)-1 (−)-1
Space group P212121 P212121
Unit cell (a, b, c, Å) 99.5, 112.2, 160.2 99.4, 112.8, 161.1
Resolution (Å) 2.0 2.03
Total measurements 836,316 499,063
Unique reflections 121,450 112,573
Completeness (%) 99.8 (99.0)* 96.4 (84.9)
Average I/σ 12.5 (3.5)* 11.1 (3.0)




Resolution 50-2.0 Å 50-2.03
Reflections 116,679 106,847
RMS deviation for
 Bond (Å) 0.0057 0.0064
 Angle 1.19° 1.20°
Average B-factor (Å2)







The numbers in parentheses are for the highest resolution shell.
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